MedTrace Logo

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

NCT00537420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 551

Last updated 2008-09-15

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.

Conditions

Interventions

DRUG

Nasal Placebo

Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.

DRUG

Placebo Capsule

Placebo capsules will be taken once daily with or without food.

DRUG

PYY3-36

Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.

DRUG

PYY3-36

Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.

DRUG

PYY3-36

Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.

DRUG

Sibutramine

Sibutramine will be taken once daily with or without food

Sponsors & Collaborators

  • Nastech Pharmaceutical Company, Inc.

    lead INDUSTRY

Principal Investigators

  • Gordon Brandt, M.D. · Nastech Pharmaceutical Company, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537420 on ClinicalTrials.gov